Erva Ozkan

6PUBLICATIONS
9CO-AUTHORS
Molecular targetsPredictive and prognostic markersBiologically active moleculesCancer diagnosisCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Mar 10, 2026
Structure-Guided Optimization and Biological Validation of 1,3,4-Thiadiazole-Based SIRT2 Inhibitors Reinforcing Channel Entrance Interactions.

Ahmet Bugra Aksel, Fikriye Ozgencil, Filiz Bakar-Ates

|Oct 11, 2024
Synergistic ferroptosis in triple-negative breast cancer cells: Paclitaxel in combination with Erastin induced oxidative stress and Ferroportin-1 modulation in MDA-MB-231 cells.

Filiz Bakar-Ates, Erva Ozkan

|Jun 13, 2024
2-(Methyl(phenyl)amino)-N-(phenyloxyphenyl)acetamide structural motif representing a framework for selective SIRT2 inhibition.

Selen Gozde Kaya, Gokcen Eren, Alberto Massarotti

|Oct 16, 2023
Cuproptosis as the new kryptonite of cancer: a copper-dependent novel cell death mechanism with promising implications for the treatment of hepatocellular carcinoma.

Erva Ozkan, Filiz Bakar-Ates

|Nov 29, 2022
Atorvastatin induces downregulation of matrix metalloproteinase-2/9 in MDA-MB-231 triple negative breast cancer cells.

Filiz Bakar-Ates, Erva Ozkan

|Nov 25, 2020
Potentiation of the Effect of Lonidamine by Quercetin in MCF-7 human breast cancer cells through downregulation of MMP-2/9 mRNA Expression.

Erva Ozkan, Filiz Bakar-Ates

Pageof 1

Frequent Collaborators

6 joint publications

Filiz Bakar-Ates

2 joint publications

Selen Gozde Kaya

2 joint publications

Gokcen Eren

2 joint publications

Alberto Massarotti